Cancer-focused Takeda Bio Dissolved, Takeda Headquarters To Continue Development
This article was originally published in PharmAsia News
Takeda Bio Development Center Ltd., a subsidiary of Takeda Pharmaceuticals carrying out domestic development of oncology products, will be dissolved and all activities will be taken over by the parent company.
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.